PREMIER Biosoft Releases SimGlycan 4.50 with major enhancements to its data handling and analysis capabilities.
Palo Alto, California -- Feb. 25, 2013, Palo Alto, PREMIER Biosoft today announced the release of a new version of SimGlycan, its comprehensive, high throughput multi-stage MS data analysis tool. This release delivers powerful data handling capability to the product. SimGlycan can now import 20,000 spectra in a project and analyze 1000 spectra in a batch run, doubling its data handling capability from the previous versions.
With this release monoisotopic mass identification for precursors is supported along with improved confidence in the search results. Users can now reduce the reporting of false positives by setting a threshold for percentage of glycosidic bonds and filter results based on instrument type and the ionization technique used. The results of the analysis can be further filtered based on the percentage match, proximity score, precursor ion intensity and perform sorting based on the precursor m/z, precursor intensity, retention time. Relative quantification of identified glycans or glycopeptides is also now possible by normalizing the observed precursor intensity values based on the intensity of an internal standard. Formate adduct (HCOO) is now supported in addition to H, Na, Mg, Li and K.
"With every release, we aim to meet the ever-growing need of analyzing large mass spectrometry data to make glycomics research both easier and faster", said Arun Apte, CEO, PREMIER Biosoft.
For details, please visit: http://www.premierbiosoft.com/glycan/index.html
About PREMIER Biosoft:
Founded in 1994, PREMIER Biosoft is led by computer scientists and biologists dedicated to producing cutting edge intuitive software for research in life sciences. The company's goal is to study the most recent innovations in life sciences and translate them into software products to aid research. For more information about the company, go to www.premierbiosoft.com. Follow PREMIER Biosoft on Twitter@PREMIERBiosoft and on Facebook.